Aquestive Therapeutics, Inc.
AQST
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $670.0M
$5.34
▼ -0.19%
P/E
-8.22
Mkt Cap
$670.0M
52-Wk Range
$2.93–$7.55
52-Week Range
$2.93 - $7.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 6.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary soluble film delivery technology enabling faster drug absorption and improved patient compliance
- Diversified portfolio across high-value therapeutic areas with significant market opportunities
- Established commercial infrastructure and FDA-approved products generating near-term revenue
- Patent-protected formulations creating barriers to entry and extended market exclusivity
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Expansion of marketed product sales and market penetration in specialty pharmaceutical segments
Value
Trading at 0.0x Large Cap Pharma peers — a discount despite the growth profile.
Momentum
Hot
+36.6% over 3m
Quality
Excellent
High-growth business (23% revenue growth, 67% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying AQST right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 11, 2026
Reported EPS of -$0.18 vs -$0.11 consensus (-71.4% surprise). Revenue of $13.8M vs $11.4M expected (+21.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-71.4%
Revenue trend · last 8Q
—
-10%
-28%
-50%
-5%
+10%
+66%
+38%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$13.5M
$11.9M
$8.7M
$10.0M
$12.8M
$13.0M
$14.4M
$13.8M
Margins · last 8Q
Gross
-79.4%
Operating
-59.5%
Profit
-165.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AQST stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related